相关实验视频
Updated: Feb 26, 2026

03:36
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
874
NAT10和E2F1协调食道状细胞癌中CKAP5介导的进展
Wenxue Wei1, Li Wei2, Ankang Zhu1
1Department of Thoracic Surgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou City, Fujian Province, China.
Journal of gastroenterology and hepatology
|February 24, 2026
概括
N-乙转移酶10 (NAT10) 通过增加细胞骨相关蛋白5 (CKAP5) mRNA稳定性来促进食道状细胞癌 (ESCC). 针对NAT10/CKAP5和E2F1/CKAP5通路可能为ESCC提供新的治疗策略.
科学领域:
- 瘤学 在瘤学方面.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 食道状细胞癌 (ESCC) 是一种侵袭性癌症.
- 在ESCC中,N-乙转移酶10 (NAT10) 被确定为潜在的致癌促进物.
研究的目的:
- 研究NAT10在ESCC进展中的作用背后的分子机制.
- 为了阐明ESCC中的NAT10/细胞骨相关蛋白5 (CKAP5) 和E2F1/CKAP5信号通路.
主要方法:
- 在体外测试中评估了细胞活力,增殖,细胞亡和侵入.
- 在体内研究中,小鼠使用了皮下异种移植.
- 分子相互作用和表达水平是使用定量PCR,免疫染,免疫组织化学,RIP,ac4C-RIP,RNA下拉,mRNA稳定性测试,光酶记者测试和ChIP-qPCR进行分析的.
主要成果:
- 在ESCC组织和细胞系中观察到NAT10上调.
- 缺乏NAT10抑制了ESCC细胞的增殖,诱导了亡,并减少了入侵.
- NAT10以ac4C依赖的方式增强了CKAP5mRNA的稳定性,而E2F1则通过转录激活了CKAP5.
- CKAP5的再表达逆转了NAT10缺乏的抗瘤作用,而E2F1通过CKAP5.5调节了ESCC的进展.
结论:
- NAT10/CKAP5和E2F1/CKAP5轴被确定为ESCC进展的关键驱动因素.
- 这些途径代表了对抗食道状细胞癌的有希望的治疗标.
相关概念视频
MAPK Signaling Cascades
8.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Tumor Progression
7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
M-Cdk Drives Transition Into Mitosis
6.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K

